Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy.
Subjects (n = 312) received either the human diploid cell rabies vaccine (HDCV) or the purified Vero cell rabies vaccine (PVRV) according to either two-injection (days 0 and 28) or three-injection (days 0, 7, and 28) primary regimens. They received a booster injection at 1 year. Rabies antibody levels were measured after the primary series and the booster and then each year for the next 10 years. The results confirm the superior long-term immunogenicity of the three-injection over the two-injection protocol. HDCV and PVRV in three doses were equally immunogenic. A booster injection at 1 year provides long-term seroconversion (titer > or = 0.5 IU/mL). Antibody titers 2 weeks after the 1-year booster allowed prediction of long-term immunity. Good responders, with titers > or = 30 IU/mL, were protected for at least 10 years. An algorithm for differentiation between good responders and poor responders with respect to vaccine booster strategies is proposed.
Strady
A
A
Centre Hospitalier Universitaire de Reims, France.
Lang
J
J
Lienard
M
M
Blondeau
C
C
Jaussaud
R
R
Plotkin
S A
SA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D002522:Chlorocebus aethiops; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006291:Health Policy; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008297:Male; D008875:Middle Aged; D011818:Rabies / Q000453:epidemiology / Q000517:prevention & control*; D011819:Rabies Vaccines; D011820:Rabies virus / Q000276:immunology*; D012307:Risk Factors; D013997:Time Factors; D014709:Vero Cells
D000914:Antibodies, Viral; D011819:Rabies Vaccines